Relapsing Remitting Multiple Sclerosis
Boys with onset of MS during puberty experienced an increased rate of relapse compared with boys with MS onset before or after puberty.
The biannual infusion is approved for the treatment of adults with relapsing and progressive forms of multiple sclerosis.
Five years after treatment, nearly 70% of patients with relapsing-remitting multiple sclerosis showed no signs of disease progression.
Previous MRI studies focused on gray matter changes only.
The authors aimed to identify confirmed disability improvement (CDI), which reflects a clinically meaningful change in EDSS score.
Differences in gut bacteria were apparent between patients with active RRMS and those in remission.
The 2 mg dose appears to be most efficacious.
If approved, the monoclonal antibody will be the first treatment indicated for both RMS and PPMS.
The company said it will continue to explore its options.
Notably, results were achieved without maintenance therapy.
At follow-up, 22 patients were cognitively impaired compared to 34 at baseline.
The monthly injectable comes with a boxed warning for severe liver injury.
Treatment with the biannual injection consistently resulted in greater achievement of NEDA compared to standard care.
Women who experience relapse and take corticosteroids may be at risk for complications.
No differences were observed among the group who switched therapy and controls.
Combined results confirmed that intrathecal LCN2 production was increased in MS patients, especially those with SPMS and PPMS.
Natalizumab treatment linked to 15.9% increase of value in JC virus.
When first-line therapies fail, physicians must consider several factors when choosing the next course of treatment for their RRMS patients.
The results suggest that addressing depression may help improve other symptoms, like pain and fatigue.
MS clinical trials have triple the success rate of those focused on other diseases.
Neurology Advisor Articles
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Seizure Monitoring Smartwatch Cleared for Use in Children
- Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS
- Can Early Initiation of Direct Oral Anticoagulants Prevent Recurrent AFib-Related Stroke?
- Online Family Problem-Solving Program May Improve Behavioral Outcomes in Older Children With TBI
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Cervical Dysfunction Needs Clarification to Identify Link With Headache
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Risk for Conversion of MS Varies With Different Therapies
- Breakdown of Blood-Brain Barrier May Drive Dementia
- FDA: Food Inspections to Resume Despite Ongoing Funding Lapse
- First Generic Version of Sabril Tablets Gets FDA Approval
- Supine Positioning After Greater Occipital Nerve Block May Improve Outcomes